Endocrine Therapy Predominant Therapeutic Option in HR+/HER2-Negative Advanced Breast Cancer
According to a retrospective cohort analysis, endocrine therapy in the first-line was found to be the predominant therapeutic option for hormone receptor-positive HER2-negative advanced breast cancer (HR+ HER2- aBC).
Included in the study were 874 adult patients with de novo or recurrent HR+ HER2- aBC who had received treatment since 2018. The primary objective was to describe the rate of CDK4/6i first-line usage. A secondary objective was to describe the patient and disease characteristics in the iCDK4/6 group, as well as those in the endocrine mono therapy, and chemotherapy groups.
Of the total patients, 45.9% were treated with CDK4/6i in combination with endocrine therapy in the first line. Of patients with visceral metastases, 50.5% were treated with CDK4/6i in the first line, compared to 42.1% of those without visceral metastases. There were 78% of the total patients treated with endocrine therapy ± targeted therapy, with 69.5% of patients with visceral metastases and 84.9% of patients without.
Source:
Stenina M, Zhukova L, Stroyakovskiy D, Karaseva VV, Tjulandin S. Treatment sequence for hormone receptor-positive HER2-negative advanced breast cancer: Results of a retrospective analysis of Russian patients diagnosed with aBC in 2014-2021. Abstract presented at: American Society of Clinical Oncology; June 3-7, 2022. Chicago, IL.
